KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBT Margin (2016 - 2025)

Historic EBT Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 26.87%.

  • Regeneron Pharmaceuticals' EBT Margin rose 15800.0% to 26.87% in Q4 2025 from the same period last year, while for Dec 2025 it was 36.47%, marking a year-over-year increase of 28100.0%. This contributed to the annual value of 36.47% for FY2025, which is 28100.0% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' EBT Margin is 26.87%, which was up 15800.0% from 46.97% recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBT Margin ranged from a high of 2122.2% in Q1 2022 and a low of 22.28% during Q1 2024
  • Moreover, its 5-year median value for EBT Margin was 40.72% (2024), whereas its average is 208.21%.
  • In the last 5 years, Regeneron Pharmaceuticals' EBT Margin surged by 20726500bps in 2022 and then tumbled by -20950700bps in 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' EBT Margin (Quarter) stood at 50.56% in 2021, then soared by 2520bps to 1324.7% in 2022, then plummeted by -97bps to 33.42% in 2023, then fell by -24bps to 25.29% in 2024, then rose by 6bps to 26.87% in 2025.
  • Its last three reported values are 26.87% in Q4 2025, 46.97% for Q3 2025, and 41.32% during Q2 2025.